Notably, the BEACON CRC study demonstrated that the combination of encorafenib and cetuximab improved overall survival, objective response rate, and progression-free survival in previously treated metastatic CRC patients with BRAF V600E mutations compared to standard chemotherapy 51. Here, BRAF is linked to colorectal carcinoma.